Physician profile
Emily Stem
NPI 1457993263
$1,656.48
in general payments reported to CMS, 2019-2025
19 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $144 · 2023: $382 · 2024: $525 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,334.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $474.80 | 2022-2025 | Veozah, Myrbetriq |
| Sage Therapeutics, LLC | $224.74 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $182.68 | 2022-2025 | Slynd |
| Abbvie INC. | $165.33 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.00 | 2023-2025 | |
| Coopersurgical, INC. | $87.14 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Supernus Pharmaceuticals, INC. | $67.72 | 2025 | Qelbree |
| Mayne Pharma Commercial LLC | $58.14 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $57.83 | 2023-2024 | Myfembree, Gemtesa |
| Ethicon US, LLC | $33.38 | 2024 | Enseal |
| Millicent US INC | $30.37 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Pfizer INC. | $26.70 | 2025 | |
| Mylan Pharmaceuticals INC. | $23.41 | 2021 | |
| Therapeuticsmd, INC. | $23.12 | 2021 | |
| Heron Therapeutics, INC. | $22.96 | 2023 | Zynrelef |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $17.94 | 2023 | Myrisk |
| Medtronic, INC. | $16.24 | 2024 | Ligasure |
| Seqirus USA INC | $15.47 | 2025 | Flucelvax, Fluad |
| Aspira Women'S Health INC | $11.51 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Stem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.